organization · Reporting owner

Samsara BioCapital GP, LLC

Disclosed activity across 6 companies

Tapewire entity: 44747
SEC CIK: 0001888829

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Kalaris Therapeutics, Inc.KLRS · Entity 6805	10% owner	May 20, 2026	May 22, 2026
Neurogene Inc.NGNE · Entity 5160	10% owner	November 26, 2024	November 27, 2024
Scholar Rock Holding CorpSRRK · Entity 3721	10% owner	October 16, 2023	October 18, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Kalaris Therapeutics, Inc.

Report date May 20, 2026 · Filed May 22, 2026

Jointly reported with AKKARAJU SRINIVAS, Samsara BioCapital, L.P., Samsara Opportunity Fund, L.P., Samsara Opportunity Fund GP, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Samsara Opportunity Fund, L.P.	2,224,147	Reported balance After 2026-05-20 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-05-20 · Purchase · Acquired 244,300 · Balance 2,224,147 F1: Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction. F2: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of its or his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Samsara BioCapital, L.P.	10,657,028	Reported balance After 2026-05-20 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-05-20 · Other · Disposed 66,906 · Balance 10,657,028 F3: Represents a pro rata, in-kind distribution, without additional consideration, and not a purchase or sale of securities, by Samsara LP in respect of redeemed interests in Samsara LP. Of the shares distributed by Samsara LP, (i) 47,498 were distributed to redeeming limited partners, (ii) 14,937 shares were distributed to Samsara BioCapital GP, LLC ("Samsara LLC"), the general partner of Samsara LP, in respect of redeemed interests of non-managing members of Samsara LLC that were retained by Samsara LLC, and (iii) 4,471 shares were distributed to Samsara BioCapital Partners, L.P. ("Samsara BioCapital Partners"), in respect of the redeemed interest of a limited partner of Samsara LP that has been acquired by Samsara BioCapital Partners. F4: The shares held by Samsara LP reflects the disposition of 244,300 shares, to Samsara Opportunity Fund as described in footnote (1), in which each of Samsara LLC and Dr. Akkaraju had no pecuniary interest. F5: Securities are held by Samsara LP. Samsara LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Samsara BioCapital GP, LLC	14,937	Reported balance After 2026-05-20 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-05-20 · Other · Acquired 14,937 · Balance 14,937 F6: Represents receipt of shares in the distribution in kind described in footnote (3). F7: Securities are held by Samsara LLC. Dr. Akkaraju has voting and investment power over the shares held by Samsara LLC and, accordingly, may be deemed to beneficially own the shares held by Samsara LLC. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Samsara BioCapital Partners, L.P.	19,408	Reported balance After 2026-05-20 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2026-05-20 · Other · Acquired 4,471 · Balance 19,408 F6: Represents receipt of shares in the distribution in kind described in footnote (3). F8: Securities are held by Samsara BioCapital Partners. Dr. Akkaraju has voting and investment power over the shares held by Samsara BioCapital Partners and, accordingly, may be deemed to beneficially own the shares held by Samsara BioCapital Partners. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction.

F2: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of its or his pecuniary interest therein.

F3: Represents a pro rata, in-kind distribution, without additional consideration, and not a purchase or sale of securities, by Samsara LP in respect of redeemed interests in Samsara LP. Of the shares distributed by Samsara LP, (i) 47,498 were distributed to redeeming limited partners, (ii) 14,937 shares were distributed to Samsara BioCapital GP, LLC ("Samsara LLC"), the general partner of Samsara LP, in respect of redeemed interests of non-managing members of Samsara LLC that were retained by Samsara LLC, and (iii) 4,471 shares were distributed to Samsara BioCapital Partners, L.P. ("Samsara BioCapital Partners"), in respect of the redeemed interest of a limited partner of Samsara LP that has been acquired by Samsara BioCapital Partners.

F4: The shares held by Samsara LP reflects the disposition of 244,300 shares, to Samsara Opportunity Fund as described in footnote (1), in which each of Samsara LLC and Dr. Akkaraju had no pecuniary interest.

F5: Securities are held by Samsara LP. Samsara LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

F6: Represents receipt of shares in the distribution in kind described in footnote (3).

F7: Securities are held by Samsara LLC. Dr. Akkaraju has voting and investment power over the shares held by Samsara LLC and, accordingly, may be deemed to beneficially own the shares held by Samsara LLC. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

F8: Securities are held by Samsara BioCapital Partners. Dr. Akkaraju has voting and investment power over the shares held by Samsara BioCapital Partners and, accordingly, may be deemed to beneficially own the shares held by Samsara BioCapital Partners. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

Neurogene Inc.

Report date November 26, 2024 · Filed November 27, 2024

Jointly reported with Samsara BioCapital, L.P., AKKARAJU SRINIVAS

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Samsara BioCapital, L.P.	1,717,127	Last balance in matching sequence After 2024-11-26 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 4 source rows Row 1 · 2024-11-26 · Purchase · Acquired 20,748 · Balance 1,689,105 F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.25 to $25.23 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Row 2 · 2024-11-26 · Purchase · Acquired 10,803 · Balance 1,699,908 F3: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.47 to $26.44 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Row 3 · 2024-11-26 · Purchase · Acquired 15,219 · Balance 1,715,127 F4: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.46 to $26.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Row 4 · 2024-11-26 · Purchase · Acquired 2,000 · Balance 1,717,127 F5: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $27.48 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.25 to $25.23 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

F3: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.47 to $26.44 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.46 to $26.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F5: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $27.48 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

Scholar Rock Holding Corp

Report date October 16, 2023 · Filed October 18, 2023

Jointly reported with Samsara BioCapital, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Samsara BioCapital, L.P.	6,788,609	Reported balance After 2023-10-16 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-10-16 · Purchase · Acquired 2,189,781 · Balance 6,788,609 F1: Shares are held by Samsara BioCapital LP ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Samsara LLC disclaims beneficial ownership in these shares except to the extent of its respective pecuniary interest therein. Dr. Akkaraju is a director of Issuer and files separate Section 16 reports.

Filing footnotes · ownership attribution and instrument terms

F1: Shares are held by Samsara BioCapital LP ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Samsara LLC disclaims beneficial ownership in these shares except to the extent of its respective pecuniary interest therein. Dr. Akkaraju is a director of Issuer and files separate Section 16 reports.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CARGO Therapeutics, Inc.

Report date May 30, 2024 · Filed June 04, 2024

Jointly reported with Samsara BioCapital, L.P., AKKARAJU SRINIVAS

Section 16 reporting ended · disclosed 2024-06-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Samsara BioCapital, L.P.	4,415,689	Reported balance After 2024-05-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-05-30 · Purchase · Acquired 294,000 · Balance 4,415,689 F1: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

Mineralys Therapeutics, Inc.

Report date March 13, 2025 · Filed March 18, 2025

Jointly reported with Samsara BioCapital, L.P.

Section 16 reporting ended · disclosed 2025-03-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Samsara BioCapital, L.P.	5,674,916	Reported balance After 2025-03-13 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-03-13 · Purchase · Acquired 600,000 · Balance 5,674,916 F1: Securities are directly held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Securities are directly held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein.

vTv Therapeutics Inc.

Report date March 05, 2024 · Filed December 06, 2024

Jointly reported with Samsara BioCapital, L.P.

Section 16 reporting ended · disclosed 2024-12-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectBy Samsara BioCapital, L.P.	206,784	Reported balance After 2024-03-05 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-03-05 · Other · Disposed 58,836 · Balance 206,784 F1: On March 5, 2024, Samsara BioCapital, L.P. ("Samsara LP") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants exercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share. F2: These securities are held by Samsara LP. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership in these securities except to the extent of its pecuniary interest therein. Dr. Akkaraju is a director of the Issuer and files separate Section 16 reports.
Pre- Funded Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01	IndirectSamsara BioCapital, L.P.	892,578	Reported balance After 2024-03-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-03-05 · Grant · Acquired 58,885 · Balance 892,578 F1: On March 5, 2024, Samsara BioCapital, L.P. ("Samsara LP") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants exercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share. F3: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise. F2: These securities are held by Samsara LP. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership in these securities except to the extent of its pecuniary interest therein. Dr. Akkaraju is a director of the Issuer and files separate Section 16 reports.

Filing footnotes · ownership attribution and instrument terms

F1: On March 5, 2024, Samsara BioCapital, L.P. ("Samsara LP") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants exercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share.

F2: These securities are held by Samsara LP. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership in these securities except to the extent of its pecuniary interest therein. Dr. Akkaraju is a director of the Issuer and files separate Section 16 reports.

F3: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 20, 2026 Filed May 22, 2026 23:47 UTC	Kalaris Therapeutics, Inc. KLRS · Entity 6805	OtherCommon Stock	4,471	$0.00	$0.00	Disclosure SEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 4 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital Partners, L.P. Disclosed balance after: 19,408 F6 · kind: Represents receipt of shares in the distribution in kind described in footnote (3). F8 · ownership.nature: Securities are held by Samsara BioCapital Partners. Dr. Akkaraju has voting and investment power over the shares held by Samsara BioCapital Partners and, accordingly, may be deemed to beneficially own the shares held by Samsara BioCapital Partners. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document
May 20, 2026 Filed May 22, 2026 23:47 UTC	Kalaris Therapeutics, Inc. KLRS · Entity 6805	OtherCommon Stock	14,937	$0.00	$0.00	Disclosure SEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital GP, LLC Disclosed balance after: 14,937 F6 · kind: Represents receipt of shares in the distribution in kind described in footnote (3). F7 · ownership.nature: Securities are held by Samsara LLC. Dr. Akkaraju has voting and investment power over the shares held by Samsara LLC and, accordingly, may be deemed to beneficially own the shares held by Samsara LLC. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document
May 20, 2026 Filed May 22, 2026 23:47 UTC	Kalaris Therapeutics, Inc. KLRS · Entity 6805	OtherCommon Stock	66,906	$0.00	$0.00	Disclosure SEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 10,657,028 F3 · kind: Represents a pro rata, in-kind distribution, without additional consideration, and not a purchase or sale of securities, by Samsara LP in respect of redeemed interests in Samsara LP. Of the shares distributed by Samsara LP, (i) 47,498 were distributed to redeeming limited partners, (ii) 14,937 shares were distributed to Samsara BioCapital GP, LLC ("Samsara LLC"), the general partner of Samsara LP, in respect of redeemed interests of non-managing members of Samsara LLC that were retained by Samsara LLC, and (iii) 4,471 shares were distributed to Samsara BioCapital Partners, L.P. ("Samsara BioCapital Partners"), in respect of the redeemed interest of a limited partner of Samsara LP that has been acquired by Samsara BioCapital Partners. F4 · balance_after: The shares held by Samsara LP reflects the disposition of 244,300 shares, to Samsara Opportunity Fund as described in footnote (1), in which each of Samsara LLC and Dr. Akkaraju had no pecuniary interest. F5 · ownership.nature: Securities are held by Samsara LP. Samsara LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document
May 20, 2026 Filed May 22, 2026 23:47 UTC	Kalaris Therapeutics, Inc. KLRS · Entity 6805	PurchaseCommon Stock	244,300	$4.83	$1,179,969.00	Disclosure SEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 2,224,147 F1 · kind: Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction. F2 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of its or his pecuniary interest therein. Read SEC document
December 18, 2025 Filed Feb 18, 2026 01:15 UTC	Kalaris Therapeutics, Inc. KLRS · Entity 6805	PurchaseCommon Stock	479,847	$10.42	$5,000,005.74	Disclosure SEC source: 0001231919-26-000166 · form4-02182026_010226.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 1,979,847 F1 · kind: Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction. F2 · balance_after: Represents the number of shares held as of the date of this filing, including the shares purchased by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund") on December 22, 2025, as reported in the reporting persons' Form 4 filed with the SEC on December 22, 2025 (the "Prior Report"). The Prior Report is deemed amended hereby. F3 · ownership.nature: Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document
March 13, 2025 Filed Mar 18, 2025 01:05 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	PurchaseCommon Stock	600,000	$13.50	$8,100,000.00	Disclosure SEC source: 0001415889-25-008275 · form4-03182025_010343.xml · nonDerivative · entry 1 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 5,674,916 F1 · ownership.nature: Securities are directly held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein. Read SEC document
November 26, 2024 Filed Nov 27, 2024 21:39 UTC	Neurogene Inc. NGNE · Entity 5160	PurchaseCommon Stock	2,000	$27.50	$55,000.00	Disclosure SEC source: 0001415889-24-027861 · form4-11272024_091125.xml · nonDerivative · entry 4 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 1,717,127 F5 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $27.48 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document
November 26, 2024 Filed Nov 27, 2024 21:39 UTC	Neurogene Inc. NGNE · Entity 5160	PurchaseCommon Stock	15,219	$26.73	$406,803.87	Disclosure SEC source: 0001415889-24-027861 · form4-11272024_091125.xml · nonDerivative · entry 3 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 1,715,127 F4 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.46 to $26.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document
November 26, 2024 Filed Nov 27, 2024 21:39 UTC	Neurogene Inc. NGNE · Entity 5160	PurchaseCommon Stock	10,803	$26.01	$280,986.03	Disclosure SEC source: 0001415889-24-027861 · form4-11272024_091125.xml · nonDerivative · entry 2 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 1,699,908 F3 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.47 to $26.44 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document
November 26, 2024 Filed Nov 27, 2024 21:39 UTC	Neurogene Inc. NGNE · Entity 5160	PurchaseCommon Stock	20,748	$24.91	$516,832.68	Disclosure SEC source: 0001415889-24-027861 · form4-11272024_091125.xml · nonDerivative · entry 1 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 1,689,105 F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.25 to $25.23 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document
May 30, 2024 Filed Jun 4, 2024 01:45 UTC	CARGO Therapeutics, Inc. CRGX · Entity 76319	PurchaseCommon Stock	294,000	$17.00	$4,998,000.00	Disclosure SEC source: 0001415889-24-015250 · form4-06042024_010623.xml · nonDerivative · entry 1 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 4,415,689 F1 · ownership.nature: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document
March 05, 2024 Filed Dec 6, 2024 21:15 UTC	vTv Therapeutics Inc. VTVT · Entity 6614	GrantPre- Funded Warrants (Right to Buy) · Derivative	58,885	Not disclosed Strike: $0.01	Not disclosed	Disclosure SEC source: 0001415889-24-028465 · form4-12062024_041204.xml · derivative · entry 2 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Samsara BioCapital, L.P. Disclosed balance after: 892,578 Underlying: Class A Common Stock · 58,885 shares Expires not disclosed F1 · kind: On March 5, 2024, Samsara BioCapital, L.P. ("Samsara LP") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants exercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share. F1 · price: On March 5, 2024, Samsara BioCapital, L.P. ("Samsara LP") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants exercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share. F3 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise. F3 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise. F2 · ownership.nature: These securities are held by Samsara LP. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership in these securities except to the extent of its pecuniary interest therein. Dr. Akkaraju is a director of the Issuer and files separate Section 16 reports. Read SEC document
March 05, 2024 Filed Dec 6, 2024 21:15 UTC	vTv Therapeutics Inc. VTVT · Entity 6614	OtherClass A Common Stock	58,836	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-028465 · form4-12062024_041204.xml · nonDerivative · entry 1 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 206,784 F1 · kind: On March 5, 2024, Samsara BioCapital, L.P. ("Samsara LP") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants exercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share. F1 · price: On March 5, 2024, Samsara BioCapital, L.P. ("Samsara LP") entered into an Exchange Agreement with the Issuer pursuant to which Samsara LP exchanged, for no additional consideration, 58,836 shares of the Issuer's Class A Common Stock for pre-funded warrants exercisable for up to 58,885 shares of the Issuer's Class A Common Stock at an exercise price of $0.01 per share. F2 · ownership.nature: These securities are held by Samsara LP. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. Samsara LLC disclaims beneficial ownership in these securities except to the extent of its pecuniary interest therein. Dr. Akkaraju is a director of the Issuer and files separate Section 16 reports. Read SEC document
February 12, 2024 Filed Feb 15, 2024 02:06 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	PurchaseCommon Stock	555,555	$13.50	$7,499,992.50	Disclosure SEC source: 0001415889-24-003859 · form4-02152024_020259.xml · nonDerivative · entry 1 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,074,916 F1 · ownership.nature: Represents securities held directly by Samsara BioCapital, L.P. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara BioCapital, L.P. ("Samsara LP") and may be deemed to beneficially own the shares held by Samsara LP. Samsara LLC disclaims beneficial ownership in these shares except to the extent of its pecuniary interest therein. Read SEC document
November 14, 2023 Filed Nov 17, 2023 00:39 UTC	CARGO Therapeutics, Inc. CRGX · Entity 76319	ConversionSeries A-2 convertible preferred stock · Derivative	1,833,623	$0.00	$0.00	Disclosure SEC source: 0001209191-23-055621 · doc4.xml · derivative · entry 5 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,833,623 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document
November 14, 2023 Filed Nov 17, 2023 00:39 UTC	CARGO Therapeutics, Inc. CRGX · Entity 76319	ConversionSeries A-1 convertible preferred stock · Derivative	884,400	$0.00	$0.00	Disclosure SEC source: 0001209191-23-055621 · doc4.xml · derivative · entry 4 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 0 Underlying: Common Stock · 884,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document
November 14, 2023 Filed Nov 17, 2023 00:39 UTC	CARGO Therapeutics, Inc. CRGX · Entity 76319	ConversionSeries Seed convertible preferred stock · Derivative	663,300	$0.00	$0.00	Disclosure SEC source: 0001209191-23-055621 · doc4.xml · derivative · entry 3 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 0 Underlying: Common Stock · 663,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document
November 14, 2023 Filed Nov 17, 2023 00:39 UTC	CARGO Therapeutics, Inc. CRGX · Entity 76319	PurchaseCommon Stock	666,666	$15.00	$9,999,990.00	Disclosure SEC source: 0001209191-23-055621 · doc4.xml · nonDerivative · entry 2 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 4,121,689 F2 · ownership.nature: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document
November 14, 2023 Filed Nov 17, 2023 00:39 UTC	CARGO Therapeutics, Inc. CRGX · Entity 76319	ConversionCommon Stock	3,381,323	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-055621 · doc4.xml · nonDerivative · entry 1 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 3,455,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document
October 16, 2023 Filed Oct 18, 2023 21:44 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	PurchaseCommon Stock	2,189,781	$6.85	$14,999,999.85	Disclosure SEC source: 0001209191-23-053111 · doc4.xml · nonDerivative · entry 1 Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 6,788,609 F1 · ownership.nature: Shares are held by Samsara BioCapital LP ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Samsara LLC disclaims beneficial ownership in these shares except to the extent of its respective pecuniary interest therein. Dr. Akkaraju is a director of Issuer and files separate Section 16 reports. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.